JANX earnings analysis
What we found in JANX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Janux Therapeutics reported a revenue of $3.73 million for Q1 2026, exceeding expectations, while net losses increased slightly to $24.36 million. The company's strong cash position stands at $957.2 million, providing sufficient funds for the next 12 months, despite ongoing significant cash burn. Management anticipates increasing operating expenses due to ongoing R&D activities.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue Exceeds Consensus
- Reported revenue of $3.73 million, above the consensus estimate of $3 million.
- Cash Position Strong
- As of March 31, 2026, cash, cash equivalents and short-term investments totaled $957.2 million.
- Reduced Operating Losses
- Loss from operations decreased to $34.21 million in Q1 2026 from $34.90 million in Q1 2025.
- Positive Collaboration Revenue
- Collaboration revenue recognized was $3.7 million for Q1 2026, up from zero in Q1 2025.
- Increased R&D Spending
- R&D expenses rose to $26.81 million in Q1 2026 from $25.06 million in Q1 2025 due to increased investments in preclinical and clinical programs.
- Sufficient Liquidity
- Management states that existing cash resources will be enough to fund operations for at least the next 12 months.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Increasing Cash Burn
- Net losses rose to $24.36 million in Q1 2026 from $23.51 million in Q1 2025, indicating higher cash burn.
- Billions in Future R&D Costs
- Management anticipates that R&D expenses will increase significantly as clinical trials progress, further straining cash flows.
- Dependence on Third-Party Collaborations
- Future success heavily relies on partnerships with entities like Bristol-Myers Squibb, which if terminated, could disrupt operations.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.39
- Segment
- Collaboration Revenue: $3.7 million
- Segment
- Total Operating Expenses: $37.9 million
What they said about what is next.
Management anticipates increasing revenues from collaboration agreements and expects operating losses to continue.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Janux reports advancement of its clinical pipeline with JANX007 moving into Phase 1b expansion cohorts (designed to inform registrational strategies) and JANX008 and JANX011 advancing into expansion / Phase 1 studies;…
- 10-Q · November 6, 2025
- Janux reported Q3 collaboration revenue of $10,000 (in thousands) compared with $439 (in thousands) in Q3 2024, producing GAAP net loss per share of $(0.39) vs $(0.51) a year ago. Operating loss remained large at…
- 10-Q · August 7, 2025
- Janux reported no collaboration revenue in Q2 2025 (versus $8,897 in Q2 2024) while operating expenses nearly doubled to $45,118 in the quarter, driving a wider net loss of $33,858 (Q2 2024: $5,959) and EPS of $(0.55)…
- 10-Q · May 8, 2024
- Janux reported collaboration revenue of $1,252,000 and a net loss of $14,760,000 (EPS -$0.30) for the quarter ended March 31, 2024. Revenue declined from $2,048,000 a year earlier while EPS improved versus prior-year…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing JANX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever